Protein aerosol for intranasal nose to brain (N2B) delivery
Martina Stützle(University of Applied Sciences Biberach), Katharina Schindowski(University of Applied Sciences Biberach), Ulrich Simon(Universität Ulm), Lucas Engelhardt(Universität Ulm), Stefan Carle(Boehringer Ingelheim (Germany)), Chrystelle Mavoungou(University of Applied Sciences Biberach), Annette Schafmeister(University of Applied Sciences Biberach)
Cited by 7
Related Papers
Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa
|Pharmaceutics|2018|415
Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits
|American Journal Of Pathology|2006|383
Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates
|Pharmaceutics|2022|93
A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery
|International Journal of Pharmaceutics|2017|55
An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80
|International Journal of Pharmaceutics|2020|47